Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database-Reference-Cited by-同舟云学术

Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database

Published:2024-03-15 Issue:3 Volume:38 Page:425-448
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Cutroneo Paola Maria,Arzenton Elena,Furci Fabiana,Scapini Fabio,Bulzomì Maria,Luxi Nicoletta,Caminati Marco,Senna Gianenrico,Moretti Ugo,Trifirò Gianluca^ORCID

Funder

Università degli Studi di Verona

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40259-024-00653-6.pdf

Reference87 articles.

1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73. https://doi.org/10.1183/09031936.00202013. (Erratum in: Eur Respir J. 2014 Apr;43(4):1216. Dosage error in article text. Erratum in: Eur Respir J. 2018 Jul 27;52(1): Erratum in: Eur Respir J. 2022 Jun 9;59(6)).

2. Vianello A, Caminati M, Andretta M, Menti AM, Tognella S, Senna G, Degli EL. Prevalence of severe asthma according to the drug regulatory agency perspective: An Italian experience. World Allergy Organ J. 2019;12(4): 100032. https://doi.org/10.1016/j.waojou.2019.100032.

3. Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075–88. https://doi.org/10.1080/03007995.2018.1505352.

4. Mavissakalian M, Brady S. The current state of biologic therapies for treatment of refractory asthma. Clin Rev Allergy Immunol. 2020;59(2):195–207. https://doi.org/10.1007/s12016-020-08776-8.

5. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L, Khurana S, Knight S, McDonald VM, Morgan RL, Ortega VE, Rigau D, Subbarao P, Tonia T, Adcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P, Custovic A, Djukanovic R, Frey U, Frankemölle B, Gibson P, Hamerlijnck D, Jarjour N, Konno S, Shen H, Vitary C, Bush A. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1): 1900588. https://doi.org/10.1183/13993003.00588-2019.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Safety Profile of Biologic Drugs for Severe Uncontrolled Asthma: A Descriptive Analysis from the Spanish Pharmacovigilance Database;Journal of Clinical Medicine;2024-07-18

2. Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis;European Respiratory Journal;2024-06-20

3. Relapsing Eosinophilia in a Severe Allergic Asthma Patient on Biological Therapy;Journal of Clinical Medicine;2024-06-11

4. Biological therapy-related ADRs in patients with severe asthma;Reactions Weekly;2024-03-23